- Home
- FTRE
as 07-26-2024 4:00pm EST
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 2.3B | IPO Year: | N/A |
| Target Price: | $31.70 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $22.15 - $41.02 | Next Earning Date: | 08-12-2024 |
| Revenue: | $3,006,900,000 | Revenue Growth: | -0.14% |
| Revenue Growth (this year): | -8.14% | Revenue Growth (next year): | 4.52% |
Stock Insider Trading Activity of Fortrea Holdings Inc. (FTRE)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hanson James S. | FTRE | General Counsel | Jun 12 '24 | Buy | $25.30 | 2,000 | $50,600.00 | 7,475 | SEC Form 4 |
| Pike Thomas | FTRE | Chief Executive Officer | May 29 '24 | Buy | $24.81 | 10,000 | $248,066.00 | 57,827 | SEC Form 4 |
Latest Fortrea Holdings Inc. News
FTRE Breaking Stock News: Dive into FTRE Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
FTRE: Lowering target price to $27.00
GlobeNewswire
10 days ago
Fortrea Announces Date for Second Quarter 2024 Financial Results and Conference Call
Argus Research
10 days ago
FTRE: Raising target price to $31.00
GlobeNewswire
16 days ago
Fortrea Appoints Robert Parks as Chief Accounting Officer
Argus Research
17 days ago
FTRE: What does Argus have to say about FTRE?
Argus Research
24 days ago
FTRE: Raising target price to $25.00
GlobeNewswire
a month ago
Fortrea Launches AI Innovation Studio to Galvanize Technology and Human Solutions to Improve Clinical Trial Delivery
GlobeNewswire
a month ago
Fortrea to Participate in Virtual Fireside Chat with Evercore ISI
Compare FTRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FTRE Fortrea Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.